# Amyloid PET | Symptoms, Causes, Tests and Treatment | OSANG > Amyloid PET uses a radioactive tracer that binds to beta-amyloid deposits to image Alzheimer's disease pathology in vivo. A negative test is in fact useful in ruling out… - Official page: https://osns.co.kr/en/encyclopedia/amyloid-pet - Organization: OSANG Neurosurgery ## Page content Diagnostic Tools ## Amyloid PET Amyloid PET Amyloid PET is a positron emission tomography test that confirms the core pathology of Alzheimer's disease in vivo by imaging the extent to which a radioactive tracer binds to beta-amyloid deposition in the brain. ## At a glance Amyloid PET uses a radioactive tracer that binds to beta-amyloid deposits to image Alzheimer's disease pathology in vivo. A negative test is in fact useful in ruling out Alzheimer's pathology. However, since the positivity rate increases with age even in asymptomatic normal elderly people, sole diagnosis is inappropriate, and selective application according to appropriate use standards is recommended. - 01Definition and Overview - 02Principle - 03Indications - 04interpretation - 05Limitations and Cautions ## Definition and Overview Amyloid PET is a positron emission tomography test that uses radioactive tracers to image beta-amyloid deposited in the brain in vivo. Beta-amyloid deposition is a core pathology of Alzheimer's disease, and is used as an auxiliary diagnostic tool in that the presence of this pathology can be confirmed without an autopsy. The test is used to confirm or rule out the presence of Alzheimer's disease pathology in the process of identifying the cause of cognitive decline. However, because the presence of deposition does not mean clinical dementia, the results are interpreted in conjunction with the clinical features. ## Principle The test uses a radioactive tracer that selectively binds to beta-amyloid, such as florbetapir. When the tracer is injected intravenously, it binds to amyloid plaques deposited in the brain, and its distribution and extent are imaged using positron emission tomography. Images are judged positive or negative based on the distribution pattern of tracers in gray matter and white matter. Positive indicates significant amyloid deposition, while negative indicates no or minimal deposition. ## Indications Amyloid PET is not a test performed on all patients with cognitive decline. It is recommended to apply selectively according to appropriate use criteria. - If there is persistent or progressive cognitive decline of unknown cause - When it is necessary to differentiate Alzheimer's disease from other diseases due to atypical clinical manifestations - When it is necessary to determine the cause of early-onset (usually before age 65) dementia In this situation, implementation is meaningful when the test results affect the direction of diagnosis and treatment. Conversely, independent testing for screening purposes in asymptomatic people is not recommended. ## interpretation ### Negative A negative test indicates the absence of significant beta-amyloid deposition in the brain and is, in fact, useful in ruling out Alzheimer's pathology. If there is cognitive decline but the test is negative, causes other than Alzheimer's disease are more actively evaluated. ### positivity Positive indicates the presence of beta-amyloid deposits. However, since a positive result does not mean dementia caused by Alzheimer's disease, it is interpreted by combining cognitive symptoms, neuropsychological tests, and other test results. ## Limitations and Cautions The most important limitation is that the positivity rate increases with age even in asymptomatic normal elderly people. Because there are cases where there are no clinical symptoms even if there is deposition, there is a risk of overdiagnosis if the diagnosis is based on a positive result alone. Therefore, amyloid PET is not a stand-alone diagnostic tool, but is positioned as an auxiliary test that is selectively applied according to appropriate use standards and interpreted in combination with clinical evaluation and other tests. Since it uses a radioactive tracer, whether to implement it or not is decided by considering the indications and benefits and burdens. ## Frequently asked questions ### Q01What kind of test is amyloid PET? This is a test in which a radioactive tracer is injected intravenously and brain images are obtained using positron emission tomography. As the tracer binds to beta-amyloid deposited in the brain, the core pathology of Alzheimer's disease can be confirmed in vivo. The filming itself takes place lying down and is completed in a relatively short period of time. ### Q02What does it mean if the test is negative? A negative score means that there is no significant beta-amyloid deposition in the brain, which is actually useful for ruling out Alzheimer's pathology. In patients with cognitive decline, if the test is negative, causes other than Alzheimer's disease are more actively searched for. ### Q03If it's positive, does it mean it's Alzheimer's disease? No. Even in asymptomatic normal elderly people, the positivity rate increases with age. Therefore, the diagnosis is not based on a positive result alone, but is interpreted in combination with cognitive symptoms, neuropsychological tests, and other test results. Independent testing is not appropriate in people without symptoms. ### Q04Who is Amyloid PET recommended for? According to the appropriate use criteria, it is recommended selectively when there is persistent or progressive cognitive decline of unknown cause and when it is necessary to differentiate Alzheimer's disease from other diseases due to atypical patterns or early onset. Implementation is meaningful when the test results affect the direction of treatment. ### Q05How is it different from a cognitive function test or MRI? Cognitive function tests evaluate the degree and area of cognitive decline, and MRI looks at structures such as brain atrophy and vascular lesions. Amyloid PET, in contrast, images beta-amyloid deposition itself, the causative pathology of Alzheimer's disease. Since the three tests provide different information, they are combined and used for diagnosis. ## Related articles - Cognitive function test - Electromyography - pupillometry test - Valsalva test This article provides general medical information and does not replace an individual diagnosis or treatment plan. Please seek a medical assessment if symptoms persist. ## Important notice This Markdown alternative helps search and AI tools understand the public page accurately. It provides general health information and does not replace an individual diagnosis or treatment.